Latest studies
- Active not recruiting
REDUCE LAP-HF III Corvia Protocol 1701
This study looks at a new treatment called the IASD System II for people with heart failure. It checks how well it works and if it's safe in everyday use, and if it improves quality of life. It's happening in Germany.
Heart FailureSwitzerland - Active not recruitingPHASE2
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
This study is looking for new ways to treat certain advanced gastrointestinal (GI) cancers. It tests a new medicine called raludotatug deruxtecan (R-DXd). Researchers want to see if this medicine can shrink or get rid of the cancer.
Gastrointestinal CancerSwitzerland - Active not recruiting
BAsel Syncope EvaLuation (BASEL IX) Study
This study looks at how we can quickly and accurately find the cause of fainting (syncope) in people over 40 who come to the emergency department. It aims to improve diagnosis and predict future health problems by using patient information, doctor assessments, and new blood tests.
SyncopeSwitzerland - Active not recruitingPHASE2
A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
This study is looking at a new medicine called BIIB080 for people with early Alzheimer's disease. Researchers want to see if it's safe and if it can slow down memory and thinking problems. They're also comparing different doses to a dummy medicine.
Mild Cognitive Impairment Due to Alzheimer's DiseaseAlzheimer's Disease DementiaSwitzerland - Active not recruitingNA
Persona Partial Knee Clinical Outcomes Study
This study looks at how well a new partial knee replacement, called the Persona Partial Knee, works. Researchers want to see if it helps people with knee pain from conditions like arthritis and how long it lasts. They'll follow patients for up to 10 years.
OsteoarthritisAvascular NecrosisTraumatic ArthritisConditional Tibial Condyle or Plateau FracturesSwitzerland - RecruitingPHASE3
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
This study is testing a new medicine called spesolimab for a skin condition called pyoderma gangrenosum (PG). It aims to see if spesolimab can help heal PG ulcers. Adults with specific types of PG ulcers can take part.
Pyoderma GangrenosumSwitzerland - RecruitingPHASE3
High Dose Steroids in Children With Stroke
This study looks at whether strong anti-inflammatory medicines (steroids) can help children recover from a type of stroke called focal cerebral arteriopathy (FCA). Scientists want to see if steroids, given alongside standard care, lead to better and faster recovery.
Paediatric StrokeSwitzerland - Active not recruitingPHASE3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
This study looks at a new drug, Tarlatamab, for people with a type of lung cancer called limited-stage small-cell lung cancer (LS-SCLC). It aims to see if Tarlatamab can help people live longer without their cancer getting worse after chemotherapy and radiotherapy.
Limited Stage Small Cell Lung CancerSmall Cell Lung CancerSwitzerland - RecruitingPHASE2
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
This study looks at a new treatment called rapcabtagene autoleucel for severe forms of a condition called ANCA-Associated Vasculitis (AAV), specifically GPA and MPA. It aims to see how well it works and if it's safe compared to current treatments.
ANCA Associated Vasculitis (AAV)Switzerland - RecruitingPHASE2, PHASE3
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
This study is testing a new drug called pumitamig, combined with usual chemotherapy and other drugs, for people with a type of lung cancer called non-small cell lung cancer. It aims to see if this new combination is safe and works well.
Non-small Cell Lung CancerSwitzerland - Active not recruiting
Endurant CHevAr New Indication Trial: ENCHANT
This study looks at a new way to treat common swellings in the main blood vessel in your tummy, called abdominal aortic aneurysms, specifically when they are near your kidneys. It uses a special 'chimney graft' technique to see how well it works and if it's safe in real-life situations.
AAA - Abdominal Aortic AneurysmSwitzerland - RecruitingPHASE3
PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
This study compares standard radiotherapy (photon therapy) with a newer type (proton therapy) for oesophageal cancer. It aims to see if proton therapy reduces side effects, especially lung problems, while still treating the cancer effectively.
Esophageal CancerRadiotherapySide EffectProton TherapySwitzerland - Active not recruitingNA
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial
This study looks at a new way to treat heart attacks by using a small pump called Impella CP®. We're comparing placing this pump for a short time before a standard heart procedure to see if it reduces heart damage more effectively.
ST Elevation (STEMI) Myocardial Infarction of Anterior WallSwitzerland - Active not recruitingPHASE1
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
This study looks at a new treatment called [177Lu]Lu-DOTA-TATE for glioblastoma, a type of brain tumour. It's testing different doses and how well it works, both on its own and with usual treatments, in people recently diagnosed or whose cancer has come back.
GlioblastomaSwitzerland - RecruitingPHASE3
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
This study looks at a new drug, dordaviprone (ONC201), for a type of brain tumour called H3 K27M-mutant diffuse glioma. It aims to see if the drug, given after radiotherapy, can help people live longer and slow down the tumour's growth.
H3 K27MGliomaSwitzerland - Active not recruitingPHASE3
ABTECT - Maintenance
This study looks at a new drug, ABX464, for people with ulcerative colitis. It's for those who haven't responded well to other treatments. The study checks if ABX464 can help keep symptoms under control over a long time and if it is safe to use.
Ulcerative ColitisSwitzerland - RecruitingPHASE2
Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis
This study is testing a new gel called TOP-N53 for finger wounds (digital ulcers) in people with a condition called systemic sclerosis. We want to see if it's safe and if it helps with pain, itching, and healing. It's for adults aged 18-69.
Digital Ulcers in Systemic SclerosisSwitzerland - Active not recruitingNA
Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System
This study looks at a new surgical plate, the A.L.P.S. Proximal Humerus Plating System, used for broken upper arm bones. It aims to confirm the plate is safe and works well after it's been made available for use.
OsteoarthritisRheumatoid ArthritisPost-Traumatic ArthritisPsoriatic ArthritisSwitzerland - Active not recruitingPHASE3
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
This study looks at different ways to treat prostate cancer using a combination of hormone therapy and radiation. Doctors want to see if a certain type of radiation, along with hormone therapy, helps patients live longer and better.
Prostate CancerSwitzerland - Active not recruitingNA
Abbott Medical - VERITAS Study
This study is looking at a new device called the Amulet™ 2. It's for people with irregular heartbeat (atrial fibrillation) who are at risk of stroke. The device aims to prevent strokes without needing long-term blood thinners.
Atrial Fibrillation (AF)StokeSwitzerland - Active not recruiting
Observational Study to Evaluate Safety and Performance of the Total Ankle Prosthesis, EasyMove®
This study looks at how well a new ankle replacement, called EasyMove, works and how safe it is over five years. It's for people who've had this ankle replacement due to severe arthritis or injury, to see how they get on in their everyday lives.
Ankle Injuries and DisordersSwitzerland - RecruitingPHASE2, PHASE3
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
This study is testing a new medicine, alpelisib, for children and adults with lymphatic malformations caused by a specific gene change (PIK3CA mutation). It will compare alpelisib to a dummy medicine to see if it can shrink the malformations and reduce symptoms.
Lymphatic MalformationsSwitzerland - RecruitingPHASE3
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
This study is for women with advanced ovarian cancer that has responded well to initial treatment. It's testing a new medicine called sac-TMT, sometimes with bevacizumab, to see if it can keep the cancer from growing or coming back for longer than standard care.
Ovarian NeoplasmsOvarian CancerSwitzerland - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
This study compares a new medicine, empasiprubart, with standard IVIg treatment for adults with CIDP. It looks at how well they work and if they are safe. Participants will receive one of these treatments, or a dummy treatment, for several months.
Chronic Inflammatory Demyelinating PolyneuropathyCIDPCIDP - Chronic Inflammatory Demyelinating PolyneuropathySwitzerland - Active not recruitingPHASE3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
This study is looking into the long-term effects and safety of a medicine called mirikizumab for people with Crohn's disease. Participants have already taken part in a related study, and this new study will help us understand how the medicine works over a longer period.
Crohn's DiseaseSwitzerland - Active not recruitingPHASE3
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
This study looks at a new drug, Sacituzumab Govitecan-hziy, for people with an aggressive type of breast cancer called triple-negative breast cancer that has spread or can't be operated on. It compares this new drug to standard treatments to see which works better at stopping the cancer from growing.
Triple Negative Breast CancerPD-L1 NegativeSwitzerland - RecruitingPHASE3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
This study is testing a new medicine, mocravimod, for adults with a type of blood cancer called AML who are having a stem cell transplant. It aims to see if mocravimod can help prevent the cancer from coming back and improve treatment success.
Adult Acute Myeloid LeukemiaSwitzerland - Active not recruitingPHASE3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
This study is for people with a specific type of advanced breast cancer (PD-L1 positive triple-negative) that hasn't been treated yet. It compares two different drug combinations to see which one works better at stopping the cancer from growing.
Triple Negative Breast CancerPD-L1 PositiveSwitzerland - RecruitingPHASE3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
This study is testing a new medicine, nucresiran, for people with a heart condition called transthyretin amyloidosis cardiomyopathy. Doctors want to see if it can improve health, reduce heart-related problems, and make patients feel better compared to a dummy medicine.
Transthyretin Amyloidosis With CardiomyopathySwitzerland - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseSwitzerland - Enrolling by invitation
A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN
This study looks at how well Refixia/REBINYN works and if it has any side effects for males with Haemophilia B over a long time. Participants will receive their usual treatment and share information about their health, bleeds, and quality of life.
Haemophilia BSwitzerland - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseSwitzerland - RecruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
This study looks at a new drug, Nizubaglustat, for Niemann-Pick Type C (NPC) disease in children and young people. It aims to see if the drug can help with movement problems and if it's safe, compared to a dummy pill.
Niemann-Pick Type C DiseaseSwitzerland - RecruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
This study is looking at a new medicine called AZ-3102 for children and young people with rare conditions like Niemann-Pick Type C, GM1 Gangliosidosis, or GM2 Gangliosidosis. It aims to see if the medicine is safe and if it helps improve their health over 18 months.
Niemann-Pick Type C DiseaseGM1 GangliosidosisGM2 GangliosidosisSwitzerland - RecruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
This study is looking at a new medicine called AZ-3102 for children and young people with GM1 or GM2 gangliosidosis. Researchers want to see if it's safe and helps improve balance and movement problems. Some people will get the medicine, others will get a dummy pill.
Gangliosidoses, GM2Gangliosidosis, GM1Switzerland - Active not recruitingPHASE3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
This study is looking at a new combination of medicines, Dato-DXd and pembrolizumab, for advanced lung cancer. It compares this combination to pembrolizumab alone to see if it's more effective and safe for people whose cancer hasn't spread and who haven't had other treatments yet.
Metastatic Non Small Cell Lung CancerSwitzerland - RecruitingPHASE3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
This study is looking at a new treatment, Xaluritamig, combined with Abiraterone, for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It compares this combination to standard treatments to see if it helps men live longer.
Metastatic Castration-resistant Prostate CancerSwitzerland - Active not recruitingPHASE3
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
This study looks at a new weekly medicine, somapacitan, for children who need help growing. It compares it to Norditropin®, a daily medicine already used. The study includes children born small, or with Turner, Noonan syndrome, or unexplained short stature, over up to 5.5 years.
SGA, Turner Syndrome, Noonan Syndrome, ISSSwitzerland - Active not recruitingPHASE3
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)
This study is testing a new medicine called Mim8 for people with haemophilia A, including those with inhibitors. Mim8 aims to prevent bleeding episodes by helping blood clot. It's for people already in other Mim8 studies.
Haemophilia AHaemophilia A With InhibitorsSwitzerland - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study looks at the long-term effects and safety of a drug called mirikizumab for people with moderate to severe ulcerative colitis. It can last up to three years, with a chance to continue treatment afterward.
Ulcerative ColitisSwitzerland - Active not recruitingPHASE3
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
This study compares two treatments, risankizumab and ustekinumab, for adults with moderate to severe Crohn's disease. Researchers want to see which treatment works best to reduce Crohn's symptoms. Both treatments are given initially by IV, then by injection.
Crohn's Disease (CD)Switzerland - Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
This study is testing a higher dose of a medicine called ocrelizumab for adults with a type of multiple sclerosis (MS) called relapsing MS. It compares the new dose to the standard dose to see if it's more effective and safe.
Multiple SclerosisSwitzerland - Active not recruitingPHASE3
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study looks at a new medicine called concizumab for people with haemophilia A or B without inhibitors. It aims to see how well it prevents bleeding and if it's safe. Participants will take the medicine daily, usually by injection under the skin, for up to 8 years.
Haemophilia A Without InhibitorsHaemophilia B Without InhibitorsSwitzerland - Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
This study looks at a new, higher dose of ocrelizumab for people with primary progressive multiple sclerosis (PPMS). Researchers want to see if this dose is safe and works better than the current approved dose to slow down the disease.
Multiple SclerosisSwitzerland - Recruiting
Patient Retrospective Outcomes (PRO)
This study looks back at anonymous medical records of adults with long-lasting pain. It compares how well different treatments worked, including those from Boston Scientific, to help doctors understand what works best for patients.
Chronic PainSwitzerland - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
Advanced Non-small Cell Lung CancerHER2 MutationSwitzerland - RecruitingPHASE2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
This study is testing a new drug, nemtabrutinib, for people with certain blood cancers like lymphoma and leukaemia. It aims to see if the drug is safe and effective in treating these conditions.
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins LymphomaChronic Lymphocytic LeukaemiaSwitzerland - Active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
This study looks at how well a medicine called risankizumab works and how safe it is for people with ulcerative colitis. It's for those who have already shown improvement with this medicine in a previous study.
Ulcerative Colitis (UC)Switzerland - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesSwitzerland - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
This study is comparing two medicines, fenebrutinib and ocrelizumab, to see which is safer and better at slowing down primary progressive multiple sclerosis (PPMS). It's for adults with PPMS and aims to understand how these treatments affect the disease progression.
Multiple Sclerosis, Primary ProgressiveSwitzerland